ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Modulation of p53 with the MDM2 Antagonist Idasanutlin, in Combination with Nilotinib Treatment, Targets Primitive CML Cells in Vitro and in Vivo
Comments 0
Login to view comments.
Click here to Login
